Replies to post #4471 on Revance Therapeutics Inc (RVNC)

[10nisman]

The bearish item is 2024-2025 guidance, specifically: “…expects to be Adjusted EBITDA positive in 2025.” Many investors probably expected EBIDTA positivity in 2024 and actual (GAAP) profitability in 2025.

Not sure how anyone was forecasting any material amount of positive EBITDA in FY 2024.

Cash flow guidance (funded to breakeven) is in-line with the Q2 earnings release a month ago.

[iwfal]

The bearish item is 2024-2025 guidance,

I’d suggest the below (related) quote, from the presentation, is equivalently bearish since q3 US aesthetics retreat vs q2 is only about 15-20%, so seasonally adjusted Daxxy grew only about 20% (not what you might expect from a ‘best in class’ product in their first year of launch)

Based on recent roll out of pricing program coupled with traditional seasonality, Q3 ‘23 product revenue has the potential to be around Q2 ‘23 levels

[10nisman]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172851256

Foley's last answer around EBITDA / Cash flow guidance is in-line with my early comment. Nobody should have been forecasting any material positive FY 2024 EBITDA, and there was no change in Management guidance other than discontinuing the OPUL business. Maybe certain market participants were baking in much rosier expectations (or some major positive news announcement would be provided today) and are selling, however, today's move doesn't align with the change in the business. I imagine most long investors came away with a positive view of the Company and the long-term expectations especially at current prices.